Hicham Majd

📢 MedTech Europe unveils Facts & Figures 2025, a snapshot of innovation and impact in Europe   Europe’s medical technology sector 🔬 continues to grow as a powerhouse of innovation and economic strength, according to Facts & Figures 2025, published today by MedTech Europe.   The report reveals a sector that is both highly innovative and deeply rooted in Europe’s economy and health systems: ✅  930,000+ people employed: more than the population of Amsterdam, with each role generating €183,000 in value. ✅  Europe is home to 38,000+ companies, 90% of them SMEs, many with fewer than 50 employees, yet driving innovation across borders. ✅  15,700+ patents filed in 2024, equal to one every 30 minutes, confirming medtech’s place among the leading fields at the European Patent Office. MedTech Europe’s Facts & Figures 2025 is the most comprehensive resource on Europe’s medical technology sector. Designed as a practical tool, the report draws on trusted sources, including Eurostat, the European Patent Office, and market analyses, to provide an authoritative overview for policymakers, healthcare professionals, and industry stakeholders.   The Facts & Figures 2025 is available here➡️https://bit.ly/3VrLpPV

199

7 Kommentare

“DeKox is emblematic of the translational approach that we want to pursue at the HZI,” says HZI Scientific Director Josef Penninger, praising the project by Till Strowig and Dr. Lisa Osbelt-Block, which has developed from a basic research question to the preparation of a clinical study within a very short time. They are developing a living biotherapeutic that is eliminating pathogenic bacteria from the gut, thus preventing infections. More about the project: https://lnkd.in/eV2d5bGN The transfer of research results into medical and pharmaceutical applications plays a central role at the HZI. Therefore, our scientists regularly transfer their results and technologies into start-ups and spin-offs. More about previous HZI spin-offs: https://lnkd.in/eXYK7GZs

68

🔬 It started with a vision — and a yellow legal pad. Over 40 years ago, Dr. Tom Grogan set out to transform cancer diagnostics. Frustrated by the slow, manual lab processes of the time and knowing the potential for synergies between diagnostics and targeted therapies, he saw the possibility to deliver faster, more accurate answers for patients. Watch Dr. Grogan’s interview and read more about the evolution of pathology and Roche Tissue Diagnostics: go.roche.com/li-VENTANA-40

426

3 Kommentare

We are proud to introduce 𝗣𝗨𝗟𝗦𝗘 — the Portable Ultra-Low-Field Scientific Exchange. PULSE is a platform that unlocks access to innovative Hyperfine technology and creates a community for researchers and developers around the world, empowering them to accelerate innovation in portable MRI technology. PULSE gives clinical researchers and developers unprecedented access to advanced tools enabling the community to: • Leverage proprietary Hyperfine research sequences, powered by Optive AI™ software • Import and adapt community-developed sequences • Access raw data “We look forward to partnering with and supporting the global community of PULSE subscribers so that together, we can unlock the revolutionary potential of portable MRI." –Maria Sainz, Hyperfine President and CEO Learn more here: https://lnkd.in/gVydhuuT #MedTech #AIinHealthcare #MRICommunity

61

Great news from our subsidiary, cecava GmbH: Precision Medicine Online, an established news and analysis portal for precision oncology, has published an in-depth article based on an interview with Saskia Biskup, MD/PhD. It covers the latest developments in individualized peptide therapy for IDH1-mutated gliomas. Based on cecava's recent press release, the article highlights the scientific background, key study results, and the next steps toward a clinical trial. We are delighted about this well-deserved attention and congratulate the entire cecava team! Learn more about cecava's pioneering approach here: https://lnkd.in/eAtAAKVu Read the full article on Precision Medicine Online here (subscription needed): https://lnkd.in/eGuKt4cX

84

2 Kommentare

Patient safety is the foundation of our work at Daiichi Sankyo. It goes beyond science and data: it is about making sure that treatments are effective, safe, and supportive for every patient, in every context. At this year’s Daiichi Sankyo Europe GmbH Patient Safety Day, a dedicated panel discussion brought us together with two patient advocates who shed light on topics that matter deeply: fertility, lactation, family well-being, and the need for transparent conversations about future plans. These perspectives remind us that safety must be defined together with patients, not only by protocols. For us at Daiichi Sankyo, patient safety means creating a continuous feedback loop: listening, learning, and applying those learnings across everything we do – from study design to treatment support. This commitment requires teamwork across all functions, and it relies on trust with the patients who share their experiences with us. Every single voice contributes to advancing safety standards and to shaping better care for the future.

139

Ypsomed Holding AG (SIX: YPSN) announced that the sale of the Ypsomed Diabetes Care business to TecMed AG, initially announced on 22 April 2025, has now been completed. This is a strategic milestone for Ypsomed as it refocuses on its market-leading position in subcutaneous self-injection solutions for pharmaceutical and biotech companies.   Walder Wyss advised Ypsomed on the carve-out of the diabetes care business and the sale to TecMed AG. The team was led by Hans-Jakob Diem (Partner, Corporate/M&A) and Dominik Hohler (Partner, Corporate/M&A) and included Letizia Schlegel (Senior Associate, Corporate/M&A), Michael Kissling (Senior Associate, Corporate/M&A), Michael Isler (Partner, IP/Data Protection and Regulatory), Kento Reutimann (Associate, IP/Data Protection), Florian Iten (Associate, Corporate/M&A), Valentin Wiesner (Managing Associate, Finance) and Valentin Freiermuth (Associate, Finance). https://lnkd.in/dg9_VQ-S

56

CARPL.ai Partners with AIRAmed GmbH to Advance Early Diagnosis of Neurodegenerative Diseases We are proud to welcome AIRAmed GmbH to the CARPL marketplace with their AI-powered brain volumetry solution, designed to support early and differential diagnosis of dementias such as Alzheimer’s and other neurodegenerative diseases. Neurodegenerative processes often remain invisible until significant neuronal loss has already occurred. By volumetrically measuring MRI scans, AIRAmed’s AI solution detects subtle brain atrophy far earlier than visual assessment alone, empowering radiologists to intervene before irreversible damage takes place. We look forward to this collaboration and bringing equitable healthcare AI to the world. #Neuroradiology #RadiologyAI #RadiologyTech #Neurocare #DegenerativeDiseases #Alzheimers #EarlyCare #PatientFirst #Collaboration #CARPL.ai #AIRAMed

43

1 Kommentar